

Lisa G Horvath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/881770/publications.pdf>

Version: 2024-02-01

90
papers

5,992
citations

87888

38
h-index

85541

71
g-index

94
all docs

94
docs citations

94
times ranked

10839
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
2	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
3	FAK signaling in human cancer as a target for therapeutics. , 2015, 146, 132-149.		317
4	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
5	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <i>Lung Cancer</i> , 2015, 89, 181-188.	2.0	253
6	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. <i>Cancer Research</i> , 2003, 63, 4196-203.	0.9	185
7	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2611-2622.	2.5	145
8	Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 15-22.	1.9	131
9	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , 2020, 9, .	6.0	104
10	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. <i>Oncogene</i> , 2003, 22, 6005-6012.	5.9	103
11	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5137-5144.	7.0	102
12	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. <i>Prostate</i> , 2004, 59, 234-242.	2.3	98
13	ERG induces taxane resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2014, 5, 5548.	12.8	96
14	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. <i>Cancer Research</i> , 2009, 69, 7696-7703.	0.9	94
15	Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1420-1424.	6.3	89
16	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
17	Lymphatic vessel density and lymph node metastasis in prostate cancer. <i>Prostate</i> , 2005, 65, 222-230.	2.3	85
18	Pathways of chemotherapy resistance in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, R103-R123.	3.1	82

#	ARTICLE	IF	CITATIONS
19	High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. <i>BJU International</i> , 2012, 109, 1794-1800.	2.5	80
20	Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro. <i>Clinical Cancer Research</i> , 2004, 10, 615-625.	7.0	79
21	Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. <i>Prostate</i> , 2008, 68, 1421-1429.	2.3	70
22	Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer. <i>Nature Communications</i> , 2017, 8, 1346.	12.8	68
23	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 949-962.	3.4	65
24	Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. <i>EBioMedicine</i> , 2020, 54, 102728.	6.1	65
25	Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 711-716.	2.5	62
26	DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns. <i>Cancer Cell</i> , 2019, 35, 297-314.e8.	16.8	62
27	Lower levels of nuclear β -catenin predict for a poorer prognosis in localized prostate cancer. <i>International Journal of Cancer</i> , 2005, 113, 415-422.	5.1	59
28	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , 2017, 25, 3485-3493.	2.2	59
29	A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 2112-2120.	5.1	54
30	Screening for <i>ROS1</i> gene rearrangements in non-small-cell lung cancers using immunohistochemistry with <i>FISH</i> confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017, 70, 402-411.	2.9	52
31	EGFR Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 585-590.	1.1	52
32	Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 148-159.	2.5	51
33	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , 2017, 128, 1166-1175.	1.5	50
34	Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. <i>Prostate</i> , 2007, 67, 1081-1090.	2.3	48
35	Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2017, 116, 1002-1011.	6.4	48
36	Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. <i>Prostate</i> , 2018, 78, 308-317.	2.3	48

#	ARTICLE	IF	CITATIONS
37	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. <i>Npj Systems Biology and Applications</i> , 2018, 4, 20.	3.0	47
38	Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 78, 173-180.	1.9	45
39	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. <i>Cancer Research</i> , 2021, 81, 4981-4993.	0.9	43
40	Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 190-201.	4.1	42
41	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 483-497.	4.4	41
42	Guidelines for whole genome bisulphite sequencing of intact and FFPE DNA on the Illumina HiSeq X Ten. <i>Epigenetics and Chromatin</i> , 2018, 11, 24.	3.9	38
43	Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 818-821.	1.9	35
44	Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. <i>Prostate</i> , 2011, 71, 1638-1645.	2.3	33
45	MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 7820.	3.3	33
46	Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. <i>BJU International</i> , 2017, 120, 651-658.	2.5	30
47	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2671-2685.	3.8	29
48	Mainstream consent programs for genetic counseling in cancer patients: A systematic review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 163-177.	1.1	29
49	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	1.6	29
50	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	1.9	28
51	Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. <i>Aging</i> , 2016, 8, 2702-2712.	3.1	27
52	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1470-1486.	3.8	26
53	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. <i>European Urology</i> , 2019, 76, 306-312.	1.9	26
54	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021, 13, 81.	8.2	25

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2488-2497.	2.5	24
56	INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival. <i>Prostate</i> , 2015, 75, 92-102.	2.3	24
57	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. <i>Science Advances</i> , 2021, 7, eabh0363.	10.3	23
58	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	6.1	23
59	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , 2020, 21, 44-58.	1.4	22
60	Expression of phosphorylated-mTOR during the development of prostate cancer. <i>Prostate</i> , 2014, 74, 1231-1239.	2.3	21
61	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. <i>Neoplasia</i> , 2019, 21, 389-400.	5.3	20
62	Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. <i>Prostate</i> , 2018, 78, 25-31.	2.3	19
63	Inhibition of guanosine monophosphate synthetase (^{GMP}) blocks glutamine metabolism and prostate cancer growth. <i>Journal of Pathology</i> , 2021, 254, 135-146.	4.5	19
64	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. <i>Investigational New Drugs</i> , 2018, 36, 886-894.	2.6	18
65	Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 622-637.	3.0	18
66	CMRF-56⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncotmmunology</i> , 2016, 5, e1168555.	4.6	17
67	Unusual Presentations of Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2001, 19, 911-915.	1.6	15
68	Discovering cancer vulnerabilities using high-throughput micro-RNA screening. <i>Nucleic Acids Research</i> , 2017, 45, 12657-12670.	14.5	15
69	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 860-870.	3.9	14
70	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , 2019, 144, 1151-1159.	5.1	13
71	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4964.	3.7	13
72	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,)		

#	ARTICLE	IF	CITATIONS
73	Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. <i>Prostate</i> , 2016, 76, 1491-1500.	2.3	11
74	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019, 22, 1-15.	4.1	11
75	Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. <i>BJU International</i> , 2010, 105, 642-647.	2.5	10
76	p53 nuclear accumulation as an early indicator of lethal prostate cancer. <i>British Journal of Cancer</i> , 2019, 121, 578-583.	6.4	10
77	Exceptional Response to ¹⁷⁷ Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	3.0	10
78	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 63-70.	3.1	10
79	Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. <i>Pathology</i> , 2011, 43, 410-419.	0.6	9
80	Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?. <i>BJU International</i> , 2015, 116, 343-350.	2.5	9
81	Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. <i>Cancers</i> , 2020, 12, 1385.	3.7	9
82	Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11-11.	1.6	6
83	Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. <i>Cancers</i> , 2022, 14, 1708.	3.7	6
84	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. <i>BMC Medicine</i> , 2022, 20, 112.	5.5	6
85	Unusual Presentations of Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2001, 19, 909-911.	1.6	2
86	Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1688-1699.	1.4	1
87	Bone disease in prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 3-4.	1.1	0
88	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 613-620.	2.3	0
89	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 44-44.	1.6	0
90	GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical) TJ ETQq0 0 0 rgBT /Overlock 10 Tf 5		